AZAnna S. Zhiryakova

Anna S. Zhiryakova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna S. Zhiryakova has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microbiota and rational empirical antibacterial therapy of anorectal abscess

    by I. N. Gorbunov, M. A. Egorkin, S. V. Polikarpova, A. S. Zhiryakova, E. E. Bolkvadze, P. Sh. Dacieva, A. N. Dadyrova

    AIM: to characterize the microbiota composition of anorectal abscess and determine the optimal empirical antibiotic therapy strategy based on microbial culture data with antibiotic susceptibility testing.PATIENTS AND METHODS: following incision and drainage of an anorectal abscess in 149 patients, samples of wound exudate were collected from postoperative wounds by swab method and subjected to bacteriological analysis. In 102 cases, only monocultures were isolated, and in 10 cases, the association of two microorganisms was observed. The absence of microbial growth was noted in 37 cases.RESULTS: among the identified microorganisms, the most prevalent were Escherichia coli (51.68%), Klebsiella pneumoniae (12.75%), and Staphylococcus aureus (7.38%). Less frequently encountered pathogens included Enterococcus faecalis (6.04%), Enterobacter cloacae (3.36%), and Pseudomonas aeruginosa (3.36%). The assessment of the isolated microorganisms' susceptibility to a range of antibiotics allowed us to determine the weighted average efficacy of each drug against the microbiota identified.CONCLUSION: the combination of ciprofloxacin and clindamycin demonstrated high clinical and economic efficacy, making it a preferred empirical therapy in patients with severe form of anorectal abscess.


  • Open Access

    Pharmacogenetic aspects of the efficacy of nonsteroidal anti-inflammatory drugs and opioid analgesics for postoperative pain relief after total joint arthroplasty

    by A. S. Zhiryakova, N. P. Denisenko, S. N. Tuchkova, A. S. Petrukhina, A. V. Kryukov, I. V. Sychev, K. B. Mirzaev, O. V. Averkov, V. I. Vechorko, E. O. Filatov, et al.

    Objective: to investigate possible associations between genetic, clinical, laboratory, and demographic parameters and the level of pain in the early postoperative (p/o) period, the need for opioid analgesics, and gastrointestinal symptoms in patients who underwent primary total knee (TKR) or hip replacement (THR).Material and methods. Sixty-one patients hospitalized for THR or TKR were included in the study. P/o pain relief was achieved using nonsteroidal anti-inflammatory drugs (NSAIDs) – ketoprofen or ketorolac – with tramadol prescribed "on demand." Pain was assessed in all patients using the numeric rating scale (NRS) on postoperative days 1–5. The amount of opioid analgesics used during hospitalization was recorded. Gene polymorphisms of CYP2C9, CYP2C8, PTGS1, PTGS2, ABCB1, CYP2D6, OPRM1, COMT, and C3orf20 were analyzed using real-time polymerase chain reaction.Results and discussion. Patients with the AC genotype of CYP2C9*3 experienced less intense pain on postoperative day 1 (4.5±1.0 vs. 7.0±2.3; p=0.03) and required fewer opioids during hospitalization (20.0±11.5 vs. 28.0±7.4 morphine equivalent units; p=0.04) compared to those with the AA genotype. Carriers of the CC genotype of the rs1045642 polymorphism of the ABCB1 gene reported less pain on day 5 (1.5±0.7 vs. 3.7±1.2; p=0.04) than those with the CT genotype. Patients with the AA genotype of rs1799971 in the OPRM1 gene required more opioids in p/o period than those with AG + GG genotypes (28.4±7.1 vs. 21.6±9.8 morphine equivalent units; p=0.03). Patients with the GG genotype of rs12496846 in the C3orf20 gene experienced more intense pain on p/o day 4 (6.0±1.41) than those with the AA genotype (2.60±1.50; p=0.002).Conclusion. Following THR and TKR, pain intensity and/or opioid use were associated with patients’ pharmacogenetic profiles in CYP2C9, ABCB1, OPRM1, and C3orf20.

  • Clinical and pharmacogenetic features of patients with upper gastrointestinal lesions at a multidisciplinary hospital: the role of nonsteroidal anti-inflammatory drugs

    by Natalia P. Denisenko, Anna S. Zhiryakova, Ivan V. Sychev, Alexander V. Kryukov, Svetlana N. Tuchkova, Olga Y. Vakulenko, Oleg V. Averkov, Valery I. Vechorko, Karin B. Mirzaev, Dmitry A. Sychev

    Objectives: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications, but their use can be associated with a number of adverse reactions, including upper gastrointestinal lesions. The aim of the study was to identify clinical and pharmacogenetic factors associated with upper gastrointestinal lesions, including those linked to NSAIDs, in patients at a multidisciplinary hospital. Methods: The study included 92 patients (mean age 59.4±16.5 years; 47 women), who underwent esophagogastroduodenoscopy during inpatient treatment. Patients’ intake of NSAIDs and gastroprotectors during the year before hospitalization was considered. Demographic, clinical, laboratory data of patients were compared between groups, including genotyping for CYP2C9*2 rs179985 , CYP2C9*3 rs1057910 , CYP2C8*3 rs11572080 , CYP2C8*3 rs10509681 , PTGS-1 rs10306135 , PTGS-1 rs12353214 , and PTGS-2 rs20417 using real-time PCR. Results: In NSAIDs + patients, PTGS1 rs10306135 AT+TT genotypes increased the chance of developing gastrointestinal complications by 5.4 times (95 % CI=1.30–22.27). In total sample, smoking (OR=3.12, 95 % CI=1.15–8.46), and alcohol intake (OR=4.09, 95 % CI=1.05–15.87) increased odds of gastrointestinal damage. In NSAIDs + patients omeprazole, famotidine and both famotidine and omeprazole during the last year were as ineffective as not taking gastroprotectors; in total sample famotidine (OR=0.19, 95 % CI=0.04–0.93) and two gastroprotectors (OR=0.13, 95 % CI=0.02–0.75) reduced the chance of upper gastrointestinal lesions. Conclusions: Pharmacogenetic features of patients may significantly contribute to the development NSAIDs-induced upper gastrointestinal injuries.


  • Open Access

    Patients’ Pharmacogenetic Characteristics and the Risk of Adverse Reactions to Non-steroidal Anti-inflammatory Drugs: Case Reports

    by A. S. Zhiryakova, N. P. Denisenko, A. V. Kryukov, K. A. Akmalova, S. N. Tuchkova, K. B. Mirzaev, D. A. Sychev

    INTRODUCTION. The variability in patient response to non-steroidal anti-inflammatory drugs (NSAIDs) may be due to genetic polymorphisms. Decreased-function or non-functional CYP2C9 alleles are known to be significant contributors to response variability, and research is being conducted on the potential contribution of polymorphisms in the PTGS1 and PTGS2 genes that encode for the NSAID targets, cyclooxygenases 1 and 2.AIM. This study aimed to demonstrate the contribution of pharmacogenetic characteristics to the development of adverse reactions to NSAIDs in clinical cases.MATERIALS AND METHODS. This study reports two clinical cases observed in a multidisciplinary hospital in Moscow. The first case report demonstrates a neurosurgical patient with spondylodiscitis who showed signs of renal failure associated with ketorolac administration during 13 days of inpatient treatment. The second case report presents a patient with gastrointestinal bleeding that developed after 3 weeks of ketorolac self-administration and ultimately required gastric resection surgery. According to real-time polymerase chain reaction results, these patients have single-nucleotide polymorphisms, including rs179985 (CYP2C9*2) and rs1057910 (CYP2C9*3) in the CYP2C9 gene, rs10306135 and rs12353214 in the PTGS1 gene, and rs20417 in the PTGS2 gene.RESULTS. The described adverse reactions to ketorolac are attributable to the patients’ pharmacogenetic characteristics and other factors (exceeding the recommended duration of ketorolac therapy, concomitant conditions, drug interactions, and older age). In the case of nephrotoxicity, the patient has the CYP2C9*1/*2 genotype, which is associated with decreased NSAID metabolism. Additionally, this patient has the PTGS1 (C>T) rs12353214 genotype, which may be associated with variations in the activity of cyclooxygenase 1 and may lead to an increased risk of adverse reactions to NSAIDs. In the case of gastrointestinal bleeding, the patient also has genetic characteristics that affect the response to NSAIDs, as the CYP2C9*1/*3 genotype is associated with significantly decreased NSAID metabolism. Patients with this genotype should take the lowest doses or switch to alternatively metabolised NSAIDs.CONCLUSIONS. To reduce the risk of nephrotoxicity and gastrointestinal bleeding in patients when prescribing ketorolac, healthcare providers should strictly follow the recommended dosing regimen and consider individual comorbidities and potential drug interactions that may potentiate adverse drug reactions. Additionally, patient risk management requires pharmacogenetic testing, including the determination of decreased-function or non-functional CYP2C9 alleles and the rs12353214 polymorphism in the PTGS1 gene.


  • Open Access

    Pharmacogenetic predictors of the safety of nonsteroidal anti-inflammatory drugs

    by A. S. Zhiryakova, N. P. Denisenko, A. V. Kryukov, A. V. Matveev, K. B. Mirzaev, D. A. Sychev

    Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently prescribed medications; however, their use may be associated with the development of numerous adverse reactions. Purpose of work: to analyze the data of studies, in which the influence of pharmacogenetic features of patients on the safety of NSAID therapy was studied. The results of numerous studies show that the safety of NSAIDs may be associated with the CYP2C9, CYP2C8, PTGS1 and PTGS2 polymorphisms. The allele frequency of these genes varies in different ethnic groups. Thus, the development of a personalized approach based on genetic, clinical and demographic, and ethnic factors of patients will improve the safety of NSAID therapy

  • Open Access

    Evaluation of the association of CES1 (rs2244613) polymorphisms with the safety of remdesivir in hospitalized patients with COVID-19

    by I. I. Temirbulatov, A. V. Kryukov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, A. A. Kachanova, Zh. A. Sozaeva, A. S. Zhiryakova, Yu. V. Shevchuk, V. I. Vechorko, et al.

    Introduction. An outbreak of novel COVID-19 infection has become a real challenge for the entire human society, and first of all for the healthcare services. The development of new drugs is a complex and lengthy process. At the beginning of the pandemic, it forced an intensive study of well-known drugs for the therapy. Remdesivir was first investigated as a potential treatment for Ebola virus. After beginning of the COVID-19 pandemic, in vitro evaluations demonstrated its activity against SARS-CoV-2. Subsequent clinical studies showed the efficacy of remdesivir in shortening the time to recovery.Aim. To evaluate the effect of the carriage of polymorphic alleles of the CES1 gene (A > C, rs2244613) on the safety profile of remdesivir therapy.Materials and methods. A total of 154 patients hospitalized with coronavirus infection were included in the study. All patients received remdesivir as etiotropic therapy in the standard regimen: 200 mg on the first day followed by 100 mg daily for 5-10 days. In the course of observations, clinical and laboratory signs of adverse events were reported. Venous blood samples were collected from each patient for pharmacogenetic studies. Genotyping was performed using the real-time polymerase chain reaction technique. Statistical analysis: вata were analysed by using IBM SPSS Statistics, Version 23.0.Results. There were no significant associations of carriage of various CES1 variants with the frequency of adverse reactions (bradycardia, nausea, vomiting) and laboratory markers of adverse events (ALT, AST, creatinine levels).Conclusion. In our study, no association was found between the carriage of CES1 gene polymorphisms and the safety parameters of remdesivir in hospitalized patients with COVID-19. Further research into the possibilities of personalizing COVID-19 therapy through pharmacogenetic testing is needed.

  • Open Access

    Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review

    by A. V. Kryukov, A. S. Zhiryakova, Yu. V. Shevchuk, A. V. Matveev, V. I. Vechorko, O. V. Averkov, S. V. Glagolev, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, et al.

    The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential adverse drug reactions (ADRs) and their predictors in etiology- and pathogenesis-oriented COVID-19 therapy. According to literature data, the main clinically significant risk factors for COVID-19 patients to develop an ADR are the duration of their hospital stay, combined use of antivirals, polypharmacy, and their history of drug allergies. The most common adverse reactions to antivirals, to virus-neutralising antibodies, and to human anti-COVID-19 immunoglobulin and convalescent plasma are, respectively, gastrointestinal and hepatobiliary disor ders; gastrointestinal disorders, neurological disorders, and allergic reactions; and transfusion reactions (fever, chills, etc.). For pathogenesis-oriented therapy with systemic glucocorticosteroids, the most characteristic ADR is hyperglycaemia. Janus kinase inhibitors and interleukin inhibitors are most often associated with gastrointestinal disorders and hypertransaminasemia; neutropenia is also characteristic of a number of interleukin inhibitors. Haemo static adverse reactions to anticoagulants depend on the patient’s dosing regimen and condition. Drug-drug interactions are a common problem in COVID-19 treatment, with the combination of nirmatrelvir and ritonavir showing the largest number of significant interactions attributed to their pharmacokinetics. Currently, there is data on the role of pharmacogenetic biomarkers in the safety and clinical outcomes of COVID-19 therapy. Thus, to improve the safety of COVID-19 therapy, an integrated approach is needed that will take into account both the clinical, demographic, and pharmacogenetic predictors of ADRs and the risk of drug-drug interactions.


  • The Effect of Carriage of CYP3A5*3 and CYP3A4*22 Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19

    by I. I. Temirbulatov, A. V. Kryukov, K. B. Mirzaev, N. P. Denisenko, S. P. Abdullaev, A. S. Zhiryakova, Y. V. Shevchuk, V. I. Vechorko, O. V. Averkov, D. A. Sychev

    Влияние носительства полиморфных вариантов CYP3A5*3 и CYP3A4*22 на безопасность терапии ремдесивиром у пациентов с COVID-19